INTRODUCTION
Multiple-gene panel (MGP) testing has rapidly replaced BRCA1/2-only testing after diagnosis of breast cancer. 1 However, genetic testing use in patients who need it seems to be low. 2, 3 One barrier to more robust uptake of MGP testing is uncertainty about its clinical utility. MGP testing yields a higher rate of pathogenic variants than BRCA1/2-only testing but with much wider variability in associated cancer risks, or penetrance. In addition, MGP testing generates higher rates of variants of unknown significance (VUSs). Taken together, there are concerns that more ambiguous findings from MGP testing may lead to unnecessary patient worry and unwarranted interventions. Indeed, some have argued that MGP testing should not replace BRCA1/2-only testing, even in patients with higher pretest risk of a pathogenic mutation, because of these concerns about patient reactions, 4 whereas others strongly disagree. 5 Current clinical guidelines that recommend genetic testing in women at elevated pretest risk of carrying a pathogenic variant do not specify how many genes should be tested. In this study, we examined the association of patient report of cancer-related worry with genetic testing type (MGP v BRCA1/2-only testing) and results (negative, VUS only, or pathogenic variant) in a large, contemporary population-based sample of patients diagnosed with breast cancer and accrued during the period immediately after introduction of MGP testing into the community. 
Background

METHODS
Study Sample and Data Collection
The iCanCare study identified women with who were 20 to 79 years of age, diagnosed with stages 0 to II breast cancer and reported to the Georgia or Los Angeles County SEER registries. 1, 6, 7 We excluded women with prior breast cancer, tumors greater than 5 cm, or more than three involved lymph nodes. We mailed survey materials and a $20 cash gift between July 2013 and August 2015. We used a modified Dillman method 8 to encourage response (median time from diagnosis to survey completion, 6 months; standard deviation [SD], 2.8 months). We sent surveys to 7,810 patients: 507 patients were ineligible because of the exclusions noted previously or were deceased, institutionalized, too ill, or unable to complete a survey in Spanish or English, leaving 7,303 patients. The survey was completed by 5,080 eligible patients (response rate, 70%) and was published previously. Survey responses were merged with SEER clinical data and genetic testing information obtained from four laboratories (Ambry Genetics, Aliso Viejo, CA; GeneDx, Gaithersburg, MD; Invitae, San Francisco, CA; Myriad Genetics, Salt Lake City, UT) that performed nearly all germline cancer genetic testing in the study regions. Test type and results were merged to 5,026 patients with complete information on all variables for SEER genetic testing linkage using a probabilistic matching strategy performed by Information Management Services (Rockville, MD). The Safe Harbor method was used to de-identify the data set before transfer to the University of Michigan for analysis. 9 The collaboration was covered under data use agreements between the University of Michigan, genetic laboratories, and Information Management Services. The research was approved by institutional review boards of the University of Michigan, Emory University, the University of Southern California, the Georgia Department of Public Health, the California State Committee for the Protection of Human Subjects, and California Cancer Registry. Signed consent was waived for the survey. Waivers of informed consent and authorization were approved, given the use of a third-party honest broker to conduct the linkage and create a de-identified data set for analyses.
Measures
We used two questions to evaluate patient worry about future cancer. Impact of Cancer Worry was the primary outcome, which was assessed using three survey items: "During the past month, how often has worrying about your cancer coming back…made you feel upset?;
ascopubs.org/journal/po JCO™ Precision Oncology 3 defined as having two or more first-degree relatives with breast cancer; any relatives with ovarian cancer, sarcoma, or male breast cancer; Ashkenazi Jewish ancestry; or a family history of a mutation-conferring risk (eg, BRCA1/2).
Statistical Analysis
We first examined cancer worry variables by test type, test results, and selected covariables. We then regressed high Impact of Cancer Worry (binary variable) on test type and selected covariables using a logistic regression model. We then repeated the analysis using test results instead of test type. We confirmed findings by repeating these analyses using high Frequency of Cancer Worry as the dependent variable. SAS version 9.4 (SAS Institute, Cary, NC) was used to compute odds ratios, adjusting for covariables and weighted for survey design and nonresponse.
RESULTS
More than half of the sample (n = 640; 60.2%) received BRCA1/2-only testing versus 423 (39.8%) who had multigene panels. A minority of tested patients reported substantial cancer worry after treatment: 11.1% (n = 130) reported high impact of cancer worry, and 15.1% (n = 162) reported high frequency of worry (worrying often or almost always in the past month). Impact of cancer worry did not substantively differ by test type, test result, or clinical or treatment factors in bivariable analyses ( Table 1) . Impact of cancer worry was higher for patients of younger age and lower education level, and for ethnic minorities. We observed similar findings in a model of frequency of cancer worry (data not shown). Figure 1 shows the results of a multivariable model regressing a binary variable indicating higher versus low impact of cancer worry on test type, controlling for selected predisposing, clinical, and treatment factors. The odds ratio for higher cancer worry was 0.81 (95% CI, 0.51 to 1.28) for MGP versus BRCA1/2-only testing. Younger age, black race (ref: white), and lower education were associated with higher cancer worry. We listed the modeling approach in Appendix Figure A1 , regressing high cancer worry on outcomes of test results and found no association; the odds ratios were 1.21 (95% CI, 0.54 to 2.68) and 0.90 (95% CI, 0.50 to 1.62) for pathogenic variant and VUS, respectively, versus a negative test (the reference group). In sensitivity analyses, we examined different permutations of the cancer worry variables, including different cut points for higher worry, and using a continuous variable, and results were consistent.
DISCUSSION
We found that the type of genetic testing patients received (MGP v BRCA1/2 only) was not associated with their report of cancer-related worry (impact or frequency). We further observed no association between patient cancer worry and test result (pathogenic variant, VUS, negative).
As noted in our prior work, cancer-related worry was associated with younger age and lower educational level, but not clinical factors. 10, 11 Strengths of this study include a large populationbased sample of patients recently diagnosed with breast cancer and accrued shortly after the advent of multigene panel testing in the community, genetic testing results from companies linked to SEER clinical data, and granular information about patients, including their report of cancer-related worry. But there are several limitations. First, we had limited information about patient perspectives and appraisal specifically related to genetic testing experiences. Second, some patients who linked to a genetic test did not recall it at the time of the survey. We excluded them from the analytic sample because we did not think it was valid to assess the association of a test type with attitudes about health risk among patients who did not recall that they had the test. Finally, generalizability of the findings are limited to two large geographic regions of the United States.
The results from this study and our prior work suggest that testing more genes versus BRCA1/2 alone does not seem to foment more negative patient reactions. Our prior research in this cohort suggested that MGP testing (v BRCA1/2-only testing) does not lead to inappropriate rates of contralateral prophylactic mastectomy. 1 Virtually all testers in this study received some form of genetic counseling, 6 and our results suggest these efforts may sufficiently frame results in a manner that did not alarm patients. Uncertainty remains about the clinical utility of MGP versus BRCA1/2-only testing after diagnosis of breast cancer. However, our results in this study and in our prior work suggest that testing more genes than BRCA1/2 does not seem to increase cancer-related worry or unwarranted interventions. 1 More research will be needed to examine the impact of genetic testing on patient outcomes in this rapidly evolving clinical context. 
